Pevjew microbiota dysbiosis: A new piece in the understanding of the carcinogenesis puzzle

Journal of Medical Microbiology

Volumn 65, Issue 12, 2016, Pages 1347-1362

  García Castillo, Valeria ^a   Sanhueza, Enrique ^a   McNerney, Eileen ^a   Onate, Sergio A ^a   García, Apolinaria ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BILE SALT; HYDROGEN SULFIDE; PROBIOTIC AGENT;

CARCINOGENESIS; CARCINOGENICITY; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; DYSBIOSIS; GENOTOXICITY; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; METABOLISM; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; ANIMAL; COLORECTAL NEOPLASMS; GASTROINTESTINAL TRACT; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATION; MICROBIOLOGY; PANCREATIC NEOPLASMS; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; COLORECTAL NEOPLASMS; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; PANCREATIC NEOPLASMS; PROBIOTICS;

EID: 85007367207     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000371     Document Type: Review

References (97)

1. Aguiar-Pulido, V., Huang, W., Suarez-Ulloa, V., Cickovski, T., Mathee, K. & Narasimhan, G. (2016). Metagenomics, metatranscriptomics, and metabolomics approaches for microbiome analysis. Evol Bioinform 12, 5-6.
2. Al-Hebshi, N., Thabet Nasher, A., Mohamed Idris, A. & Chen, T. (2015). Robust species taxonomy assignment algorithm for 16S rRNA NGS reads: application to oral carcinoma samples. J Oral Microbiol 7, 1-9.
3. Arslan, N. (2014). Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 20, 16452-16463.
4. Arthur, J. C. & Jobin, C. (2011). The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis 17, 396-409.
5. Barrett, R., Kuzawa, C. W. & McDade, T. A. G. (1998). Emerging and reemerging infectious diseases: the third epidemiologic transition. Annu Rev Anthropol 27, 247-271.
6. Belizário, J. E. & Napolitano, M. (2015). Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol 6, 1-16.
7. Blaser, M. J. (2006). Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep 7, 956-960.
8. Blaser, M. J. & Falkow, S. (2009). What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 7, 887-894.
9. Blumberg, R. & Powrie, F. (2012). Microbiota, disease, and back to health: a metastable journey. Sci Transl Med 4, 137rv7.
10. Boleij, A., Hechenbleikner, E. M., Goodwin, A. C., Badani, R., Stein, E. M., Lazarev, M. G., Ellis, B., Carroll, K. C., Albesiano, E. & other authors (2015). The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 60, 208-215.
11. Bultman, S. J. (2014). Emerging roles of the microbiome in cancer. Carcinogenesis 35, 249-255.
12. Cesaro, C., Tiso, A., Del Prete, A., Cariello, R., Tuccillo, C., Cotticelli, G., Del Vecchio Blanco, C. & Loguercio, C. (2011). Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 43, 431-438.
13. Cho, I. & Blaser, M. J. (2012). The human microbiome: at the interface of health and disease. Nat Rev Genet 13, 260-270.
14. Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. (2012). The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258-1270.
15. Costello, E. K., Lauber, C. L., Hamady, M., Fierer, N., Gordon, J. I. & Knight, R. (2009). Bacterial community variation in human body habitats across space and time. Science 326, 1694-1697.
16. Dapito, D. H., Mencin, A., Gwak, G. Y., Pradere, J. P., Jang, M. K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A. & other authors (2012). Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504-516.
17. Darnaud, M., Faivre, J. & Moniaux, N. (2013). Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 58, 385-387.
18. Dewhirst, F. E., Chen, T., Izard, J., Paster, B. J., Tanner, A. C., Yu, W. H., Lakshmanan, A. & Wade, W. G. (2010). The human oral microbiome. J Bacteriol 192, 5002-5017.
19. Dickson, R. P., Martinez, F. J. & Huffnagle, G. B. (2014). The role of the microbiome in exacerbations of chronic lung diseases. Lancet 384, 691-702.
20. Dickson, R. P. & Huffnagle, G. B. (2015). The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathog 11, e1004923.
21. Dietert, R. R. & Dietert, J. M. (2015). The microbiome and sustainable healthcare. Healthcare 3, 100-129.
22. Dietert, R. R. & Silbergeld, E. K. (2015). Biomarkers for the 21st century: listening to the microbiome. Toxicol Sci 144, 208-216.
23. D’Argenio, V. & Salvatore, F. (2015). The role of the gut microbiome in the healthy adult status. Clin Chim Acta 451, 97-102.
24. Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C. & Flavell, R. A. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13, 759-771.
25. Farrell, J. J., Zhang, L., Zhou, H., Chia, D., Elashoff, D., Akin, D., Paster, B. J., Joshipura, K. & Wong, D. T. (2012). Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582-588.
26. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D. & Bray, F. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer [Available from: http://globocan.iarc.fr].
27. Francescone, R., Hou, V. & Grivennikov, S. I. (2014). Microbiome, inflammation, and cancer. Cancer J 20, 181-189.
28. Fritz, J. V., Desai, M. S., Shah, P., Schneider, J. G. & Wilmes, P. (2013). From meta-omics to causality: experimental models for human microbiome research. Microbiome 1, 14.
29. Fung, T. C., Artis, D. & Sonnenberg, G. F. (2014). Anatomical localization of commensal bacteria in immune cell homeostasis and disease. Immunol Rev 260, 35-49.
30. Gagnière, J., Raisch, J., Veziant, J., Barnich, N., Bonnet, R., Buc, E., Bringer, M. A., Pezet, D. & Bonnet, M. (2016). Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 22, 501-518.
31. Garrett, W. S. (2015). Cancer and the microbiota. Science 348, 80-86.
32. Greer, J. B. & O’Keefe, S. J. (2011). Microbial induction of immunity, inflammation, and cancer. Front Physiol 6, 168.
33. Greub, G. (2012). Culturomics: a new approach to study the human microbiome. Clin Microbiol Infect 18, 1157-1159.
34. Gui, Q. F., Lu, H. F., Zhang, C. X., Xu, Z. R. & Yang, Y. H. (2015). Wellbalanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 14, 5642-5651.
35. Guinane, C. M. & Cotter, P. D. (2013). Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 6, 295-308.
36. Hara, E. (2015). Relationship between obesity, gut microbiome and hepatocellular carcinoma development. Dig Dis 33, 346-350.
37. Hassan, M., El-khattouti, A. & Tandon, R. (2013). Commensal microbiota in cancer development and therapy. JSM Microbiol 1, 19-21.
38. He, J., Li, Y., Cao, Y., Xue, J. & Zhou, X. (2015). The oral microbiome diversity and its relation to human diseases. Folia Microbiol 60, 69-80.
39. Hebert, E. F., Divi, R. L. & Verma, M. (2015). Microbiome analysis: trends in cancer epidemiology, challenges and opportunities. Int J Cancer Res Mol Mech 1, 1-7.
40. Hines, I. N., Son, G. & Kremer, M. (2010). Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract 2010, 13.
41. Hooper, L. V. & Macpherson, A. J. (2010). Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10, 159-169.
42. Hooper, L. V., Littman, D. R. & Macpherson, A. J. (2012). Interactions between the microbiota and the immune system. Science 336, 1268-1273.
43. Houghton, A. M. (2013). Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13, 233-245.
44. Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T. & other authors (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967-970.
45. Kamada, N. & Núñez, G. (2013). Role of the gut microbiota in the development and function of lymphoid cells. J Immunol 190, 1389-1395.
46. Kerr, D. (2003). Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 3, 615-622.
47. Khan, A. A., Shrivastava, A. & Khurshid, M. (2012). Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim Biophys Acta Rev 1826, 331-337.
48. Khurana, S. (2012). Human microbiome and cancer: an insight. Indian J Microbiol 52, 519-520.
49. Klaunig, J. E., Kamendulis, L. M. & Hocevar, B. A. (2010). Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38, 96-109.
50. Liaskou, E., Wilson, D. V. & Oo, Y. H. (2012). Innate Immune Cells in Liver Inflammation. Mediators Inflamm 2012, 1-21.
51. Logan, A. C., Jacka, F. N. & Prescott, S. L. (2016). Immune-microbiota interactions: dysbiosis as a global health issue. Curr Allergy Asthma Rep 16, 13.
52. Louis, P., Hold, G. L. & Flint, H. J. (2014). The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12, 661-672.
53. Mager, D. L., Haffajee, A. D., Devlin, P. M., Norris, C. M., Posner, M. R. & Goodson, J. M. (2005). The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med 3, 27.
54. Marchesi, J. R., Dutilh, B. E., Hall, N., Peters, W. H., Roelofs, R., Boleij, A. & Tjalsma, H. (2011). Towards the human colorectal cancer microbiome. PLoS One 6, e20447.
55. Melkamu, T., Qian, X., Upadhyaya, P., O’Sullivan, M. G. & Kassie, F. (2013). Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer. Vet Pathol 50, 895-902.
56. Meurman, J. H. (2010). Oral microbiota and cancer. J Oral Microbiol 2, 1-10.
57. Meza García, G., Muñoz Ibarra, J. J., Paez Valencia, C., Cruz Legorreta, B. & Aldape Barrios, B. (2009). [Oral cavity squamous cells carcinoma, 5 years experience in a third level social assistence center, in Mexico city]. Avances Odontoestomatol 25, 19-28 (in Spanish).
58. Michaud, D. S., Joshipura, K., Giovannucci, E. & Fuchs, C. S. (2007). A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst 99, 171-175.
59. Minemura, M. & Shimizu, Y. (2015). Gut microbiota and liver diseases. World J Gastroenterol 21, 1691-1702.
60. Mitsuhashi, K., Nosho, K., Sukawa, Y., Matsunaga, Y., Ito, M., Kurihara, H., Kanno, S., Igarashi, H., Naito, T. & other authors (2015). Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6, 1-12.
61. Morens, D. M. & Fauci, A. S. (2013). Emerging infectious diseases: threats to human health and global stability. PLoS Pathog 9, e1003467.
62. Nagy, K. N., Sonkodi, I., Szöke, I., Nagy, E. & Newman, H. N. (1998). The microflora associated with human oral carcinomas. Oral Oncol 34, 304-308.
63. Ochi, A., Nguyen, A. H., Bedrosian, A. S., Mushlin, H. M., Zarbakhsh, S., Barilla, R., Zambirinis, C. P., Fallon, N. C., Rehman, A. & other authors (2012). Myd88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209, 1671-1687.
64. Ohtani, N. (2015). Microbiome and cancer. Semin Immunopathol 37, 65-72.
65. Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A. & Brown, P. O. (2007). Development of the human infant intestinal microbiota. PLoS Biol 5, 1556-1573.
66. Perez-Chanona, E. & Trinchieri, G. (2016). The role of microbiota in cancer therapy. Curr Opin Immunol 39, 75-81.
67. Petersen, C. & Round, J. L. (2014). Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16, 1024-1033.
68. Pevsner-Fischer, M., Tuganbaev, T., Meijer, M., Zhang, S. H., Zeng, Z. R. & Elinav, E. (2016). Role of the microbiome in non-gastrointestinal cancers. World J Clin Oncol 7, 200-214.
69. Plottel, C. S. & Blaser, M. J. (2011). Microbiome and malignancy. Cell Host Microbe 10, 324-335.
70. Pragman, A. A., Kim, H. B., Reilly, C. S., Wendt, C. & Isaacson, R. E. (2012). The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 7, e47305.
71. Pushalkar, S., Mane, S. P., Ji, X., Li, Y., Evans, C., Crasta, O. R., Morse, D., Meagher, R., Singh, A. & Saxena, D. (2011). Microbial diversityin saliva of oral squamous cell carcinoma. FEMS Immunol Med Microbiol 61, 269-277.
72. Rajilić-Stojanović, M. (2013). Function of the microbiota. Best Pract Res Clin Gastroenterol 27, 5-16.
73. Ridlon, J. M., Kang, D. J. & Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47, 241-259.
74. Roh, Y. S. & Seki, E. (2013). Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol 28, 38-42.
75. Rubinstein, M. R., Wang, X., Liu, W., Hao, Y., Cai, G. & Han, Y. W. & Yiping, H. (2013). Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/b-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195-206.
76. Schippa, S. & Conte, M. (2014). Dysbiotic events in gut microbiota:impact on human health. Nutrients 6, 5786-5805.
77. Schmidt, B. L., Kuczynski, J., Bhattacharya, A., Huey, B., Corby, P. M., Queiroz, E. L., Nightingale, K., Kerr, A. R., DeLacure, M. D. & other authors (2014). Changes in abundance of oral microbiota associated with oral cancer. PLoS One 9, e98741.
78. Schwabe, R. F. & Jobin, C. (2013). The microbiome and cancer. Nat Rev Cancer 13, 800-812.
79. Sears, C. L. & Garrett, W. S. (2014). Microbes, microbiota, and colon cancer. Cell Host Microbe 15, 295-305.
80. Sheflin, A. M., Whitney, A. K. & Weir, T. L. (2014). Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep 16, 406.
81. Sze, M. A., Hogg, J. C. & Sin, D. D. (2014). Bacterial microbiome of lungs in COPD. Int J COPD 9, 229-238.
82. Tezal, M., Sullivan, M. A., Hyland, A., Marshall, J. R., Stoler, D., Reid, M. E., Loree, T. R., Rigual, N. R., Merzianu, M. & other authors (2009). Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 18, 2406-2412.
83. Tsiaoussis, G. I., Assimakopoulos, S. F., Tsamandas, A. C., Triantos, C. K. & Thomopoulos, K. C. (2015). Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World J Hepatol 7, 2058-2068.
84. Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-liggett, C., Knight, R. & Gordon, J. I. (2007). The Human Microbiome Project: exploring the microbial part of ourselves in a changing world. Nature 449, 804-810.
85. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C. & other authors (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971-976.
86. Vineis, P., Schatzkin, A. & Potter, J. D. (2010). Models of carcinogenesis: an overview. Carcinogenesis 31, 1703-1709.
87. Vizcaino, M. I. & Crawford, J. M. (2015). The colibactin warhead crosslinks DNA. Nat Chem 7, 411-417.
88. Walsh, C. J., Guinane, C. M., O’Toole, P. W. & Cotter, P. D. (2014). Beneficial modulation of the gut microbiota. FEBS Lett 588, 4120-4130.
89. Wang, L. & Ganly, I. (2014). The oral microbiome and oral cancer. Clin Lab Med 34, 711-719.
90. Wu, S., Rhee, K. J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H. R., Huso, D. L., Brancati, F. L., Wick, E. & other authors (2009). A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15, 1016-1022.
91. Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H. & other authors (2013). Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97-101.
92. Yu, L. X., Yan, H. X., Liu, Q., Yang, W., Wu, H. P., Dong, W., Tang, L., Lin, Y., He, Y. Q. & other authors (2010). Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52, 1322-1333.
93. Yu, G., Gail, M. H., Consonni, D., Carugno, M., Humphrys, M., Pesatori, A. C., Caporaso, N. E., Goedert, J. J., Ravel, J. & other authors (2016). Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol 17, 163.
94. Zackular, J. P., Baxter, N. T., Iverson, K. D., Sadler, W. D., Petrosino, J. F., Chen, G. Y. & Schloss, P. D. (2013). The gut microbiome modulates colon tumorigenesis. MBio 4, e00692-12.
95. Zambirinis, C. P., Pushalkar, S., Saxena, D. & Miller, G. (2014). Pancreatic cancer, inflammation, and microbiome. Cancer J 20, 195-202.
96. Zeller, G., Tap, J., Voigt, A. Y., Sunagawa, S., Kultima, J. R., Costea, P. I., Amiot, A., Böhm, J., Brunetti, F. & other authors (2014). Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 10, 766.
97. Zong, A., Cao, H. & Wang, F. (2012). Anticancer polysaccharides from natural resources: a review of recent research. Carbohydr Polym 90, 1395-1410